Similar articles

• Rivaroxaban and recurrent stroke prevention in AF.

  Gorelick PB. Gorelick PB. Lancet Neurol. 2012 Apr;11(4):295-7. doi: 10.1016/S1474-4422(12)70044-3. Epub 2012 Mar 7. Lancet Neurol. 2012. PMID: 22402055 No abstract available.
• Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

  Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators. Hankey GJ, et al. Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7. Lancet Neurol. 2012. PMID: 22402056 Clinical Trial.
• J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan.

  Yasaka M. Yasaka M. Circ J. 2012;76(9):2086-7. doi: 10.1253/circj.cj-12-0923. Epub 2012 Jul 28. Circ J. 2012. PMID: 22850289 No abstract available.
• [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].

  Kovács T. Kovács T. Orv Hetil. 2014 Oct 19;155(42):1655-60. doi: 10.1556/OH.2014.30021. Orv Hetil. 2014. PMID: 25305723 Review. Hungarian.
• [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].

  Koziński M, Obońska K, Kubica A, Navarese EP, Kubica J. Koziński M, et al. Kardiol Pol. 2012;70(10):1053-60. Kardiol Pol. 2012. PMID: 23080100 Review. Polish. No abstract available.